SCHEMBL6354490

SCHEMBL6354490

O=C(NCc1c(Cl)cccc1Oc1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.74
ALDH1A1 P00352 3/20 0.69
MAPT P10636 2/20 0.69
KMT2A Q03164 1/20 0.69
L3MBTL1 Q9Y468 3/20 0.65
MAPK8 P45983 2/20 0.65
TDP1 Q9NUW8 1/20 0.65
FABP3 P05413 1/20 0.60
FABP4 P15090 1/20 0.60
GAA P10253 2/20 0.58
HPGD P15428 2/20 0.58
HTT P42858 1/20 0.58
ATM Q13315 1/20 0.58
POLB P06746 1/20 0.53
DPP4 P27487 1/20 0.50
P2RX7 Q99572 1/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356156 0.89 ALDH1A1 (0.75) LMNAALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL6361630 0.85 LMNA (0.68) LMNAALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL6357279 0.84 HPGD (0.63) LMNAALDH1A1MAPTKMT2AHPGD
SCHEMBL6355252 0.84 SGMS2 (0.61) LMNAALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL6356715 0.78 LMNA (0.49) LMNAALDH1A1MAPTKMT2AHPGD
SCHEMBL5645103 0.77 HPGD (0.62) LMNAALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL7694962 0.77 EGLN1 (0.61) LMNAALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL6362683 0.77 ATM (0.55) LMNAHPGDATMP2RX7
SCHEMBL6356702 0.76 MAPK8 (0.57) LMNAALDH1A1KMT2AL3MBTL1MAPK8
SCHEMBL21966270 0.75 FABP3 (1.00) LMNAALDH1A1MAPTKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 LMNA 1197/4885ALDH1A1 1194/4885MAPT 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.